NAMI - National Alliance on Mental Illness Home | About NAMI | Contact Us | En Espanol  | Donate  
Find
  Advanced Search  
 

Sign In
myNAMI
Communities
Register and Join
Donate
What's New
State & Local NAMIs
Advocate Magazine
NAMI Newsroom
NAMI Store
NAMIWALKS
National Convention
Special Needs Estate Planning
NAMI Travel

  Sharing Hope: Understanding Mental Health
  Compartiendo Esperanza
  Resources
  NAMI en Español
  ¡Avanzamos!
  Update: News, Events and Featured Resources
 Living With
  Schizophrenia
  Major Depression
  Bipolar Disorder
  Anxiety Disorders
  OCD
  Other Mental Illnesses

Print this page
Graphic Site
Log Out
 | Print this page | 
 | 
Anxiety_Disorders

Facts on Access to Medications for People
with Depressive, Bipolar and Anxiety Illnesses

The Policymaker's Resource

"The past decade has seen an outpouring of new drugs introduced for the treatment of mental illness.  New medications for the treatment of depression...are among the achievements stoked by research advances in both neuroscience and molecular biology." 

U.S. Surgeon General Report on Mental Health, 1999


Medications for People with Depressive, Bipolar and Anxiety Disorders Should be Exempt from Restrictive Public Policies

 
  • Unlike many medications that treat other illnesses, medications that treat depressive, bipolar and anxiety disorders cannot be used interchangeably.
 
  • Because of the biologic differences among patients, medications that treat these disorders work differently for each person.
 
  • Also, because the brain is such a complex organ and these disorders are so complex, medications affect each person’s brain in a very different way.
 
  • The side effects of these medications can be extremely serious, and vary with each patient. The worse the side effects, the less likely a patient will be able to stay on treatment.
 
  • Forcing physicians to change medications that treat depressive, bipolar and anxiety disorders interferes with clinical decision making. It can weeks or months to determine if a medication works, and if not, additional weeks with no medication is required before a new one is tried. Each failed episode results in suffering and possible worsening of a patient’s condition.
 
  • Access to medications for people with these disorders is essential for achieving the best possible clinical outcome as quickly as possible, which leads to the most cost-effective policy for policymakers and states.
 
  • These disorders are three of the leading disabilities in the U.S. Access to medications for these disorders ensures effective and faster treatment, thereby returning people to work earlier.
  • No real cost savings, even in the short term, will result from Medicaid policies that restrict medication choices for people with these disorders.
 
  • Access to medications is critically important based on the unique nature of the medications and the individual characteristics of people with these disorders. State legislators should preserve and/or restore state funding for medications for people living with these illnesses.

Policymaker's Resource Contents

Introduction

Patient's Responsibility

Restrictive Formularies

Positive Effects of Open Access to Medications are Enormous

The Evidence Base for Newer Anti-Depressant Medications

Conclusion


Policymakers Toolkit Home


Related Files

Facts on Access to Medications for People with Mood Disorders: The Policymakers Resource (PDF File)

 | Print this page | 
 | 

Donate

Support NAMI to help millions of Americans who face mental illness every day.

Donate today

Speak Out

Inspire others with your message of hope. Show others they are not alone.

Share your story

Get Involved

Become an advocate. Register on NAMI.org to keep up with NAMI news and events.

Join NAMI Today
Home  |  myNAMI  |  About NAMI  |  Contact Us  |  Jobs  |  SiteMap

Copyright © 1996 - 2011 NAMI. All Rights Reserved.